232 related articles for article (PubMed ID: 22046024)
1. Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics.
Scher HI; Nasso SF; Rubin EH; Simon R
Clin Cancer Res; 2011 Nov; 17(21):6634-40. PubMed ID: 22046024
[TBL] [Abstract][Full Text] [Related]
2. Biomarker enrichment considerations in oncology early development single-arm studies.
Tian H; Liu K
J Biopharm Stat; 2018; 28(2):282-291. PubMed ID: 28934023
[TBL] [Abstract][Full Text] [Related]
3. Biomarker threshold adaptive designs for survival endpoints.
Diao G; Dong J; Zeng D; Ke C; Rong A; Ibrahim JG
J Biopharm Stat; 2018; 28(6):1038-1054. PubMed ID: 29436940
[TBL] [Abstract][Full Text] [Related]
4. Genomic Alteration-Driven Clinical Trial Designs in Oncology.
Simon R
Ann Intern Med; 2016 Aug; 165(4):270-8. PubMed ID: 27214515
[TBL] [Abstract][Full Text] [Related]
5. An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpoints.
Jenkins M; Stone A; Jennison C
Pharm Stat; 2011; 10(4):347-56. PubMed ID: 22328327
[TBL] [Abstract][Full Text] [Related]
6. Achieving the goals of effective, safe, and individualized cancer care.
Roberts SA; Karnes EK; Allen JD; Benner JS; Sigal EV; McClellan M
Clin Cancer Res; 2011 Nov; 17(21):6632-3. PubMed ID: 22046023
[No Abstract] [Full Text] [Related]
7. Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.
Li W; Chen C; Li X; Beckman RA
Stat Med; 2017 May; 36(12):1843-1861. PubMed ID: 28303586
[TBL] [Abstract][Full Text] [Related]
8. Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.
Antoniou M; Jorgensen AL; Kolamunnage-Dona R
PLoS One; 2016; 11(2):e0149803. PubMed ID: 26910238
[TBL] [Abstract][Full Text] [Related]
9. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
10. Drug-biomarker co-development in oncology - 20 years and counting.
Twomey JD; Brahme NN; Zhang B
Drug Resist Updat; 2017 Jan; 30():48-62. PubMed ID: 28363335
[TBL] [Abstract][Full Text] [Related]
11. The phase II/III transition. Toward the proof of efficacy in cancer clinical trials.
Fazzari M; Heller G; Scher HI
Control Clin Trials; 2000 Aug; 21(4):360-8. PubMed ID: 10913810
[TBL] [Abstract][Full Text] [Related]
12. The evolving potential of companion diagnostics.
Khoury JD
Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
[TBL] [Abstract][Full Text] [Related]
13. Designing precision medicine trials to yield a greater population impact.
Zhao YQ; LeBlanc ML
Biometrics; 2020 Jun; 76(2):643-653. PubMed ID: 31598964
[TBL] [Abstract][Full Text] [Related]
14. Opportunities and challenges in the era of molecularly targeted agents and radiation therapy.
Lin SH; George TJ; Ben-Josef E; Bradley J; Choe KS; Edelman MJ; Guha C; Krishnan S; Lawrence TS; Le QT; Lu B; Mehta M; Peereboom D; Sarkaria J; Seong J; Wang D; Welliver MX; Coleman CN; Vikram B; Yoo S; Chung CH; ;
J Natl Cancer Inst; 2013 May; 105(10):686-93. PubMed ID: 23503600
[TBL] [Abstract][Full Text] [Related]
15. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development.
Bando H; Takebe N
Jpn J Clin Oncol; 2015 Nov; 45(11):1001-6. PubMed ID: 26423340
[TBL] [Abstract][Full Text] [Related]
16. Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint.
Michiels S; Potthoff RF; George SL
Stat Med; 2011 Jun; 30(13):1502-18. PubMed ID: 21344471
[TBL] [Abstract][Full Text] [Related]
17. Inference for multimarker adaptive enrichment trials.
Simon R; Simon N
Stat Med; 2017 Nov; 36(26):4083-4093. PubMed ID: 28795420
[TBL] [Abstract][Full Text] [Related]
18. [Precision medicine from experimental to clinical applications in oncology].
Normanno N
Recenti Prog Med; 2015 Dec; 106(12):597-600. PubMed ID: 26780068
[TBL] [Abstract][Full Text] [Related]
19. Precision medicine clinical trials: defining new treatment strategies.
Heckman-Stoddard BM; Smith JJ
Semin Oncol Nurs; 2014 May; 30(2):109-16. PubMed ID: 24794084
[TBL] [Abstract][Full Text] [Related]
20. Reinventing clinical trials: a review of innovative biomarker trial designs in cancer therapies.
Lin JA; He P
Br Med Bull; 2015 Jun; 114(1):17-27. PubMed ID: 25921239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
